Monopar Highlights uPAR Radiopharma Cancer Target Data at 2024 SNMMI Meeting

Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company, has unveiled new data from the preclinical development of their pioneering radiopharma program, MNPR-101-Zr. The findings were presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in Toronto, Canada. 

Monopar's research focuses on the urokinase plasminogen activator receptor (uPAR) as a target for radiopharmaceutical cancer treatments for solid tumors. The data highlighted the effectiveness of MNPR-101 as a targeting agent against uPAR. Specifically, the study demonstrated significant, durable tumor uptake of the Zr-89 radiolabeled MNPR-101 (MNPR-101-Zr) in human tumor xenograft mouse models, including triple-negative breast, colorectal, and pancreatic cancers.

Monopar has achieved higher tumor uptake and greater drug stability with the optimized MNPR-101-Zr construct while reducing accumulation in bone and healthy tissues. This development marks a promising advancement in radiopharmaceutical treatments for cancer.

The company has recently commenced a first-in-human Phase 1 imaging and dosimetry clinical trial for advanced cancer patients using MNPR-101-Zr. Renowned radiopharmaceutical physician Prof. Rodney Hicks, founder of the Melbourne Theranostic Innovation Centre (MTIC), is leading the study. More details about this clinical trial can be found under the identifier NCT06337084 on ClinicalTrials.gov.

Monopar Therapeutics Inc. is dedicated to developing innovative cancer treatments, with MNPR-101-Zr in Phase 1 for imaging advanced cancers and MNPR-101 radio-immuno-therapeutic (RIT) in the late preclinical stage for treating advanced cancers.

The company issued a forward-looking statement, cautioning that the data presented are from preclinical models and may not directly translate to human clinical outcomes. They outlined potential risks such as the possibility that future data may not be as promising, challenges in enrolling patients for the Phase 1 trial, and the risk of unexpected adverse effects from MNPR-101-Zr.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!